Our strategic plan for 2024 will optimize the utilization of our devices, maximize operational efficiency, and ultimately, improve our bottom line. These adjustments reflect our proactive stance in ensuring STRATA operates at a sustainable and competitive cost base, allowing us to invest more deeply in growth and innovation. The full financial impact of these changes is anticipated by the end of 2024. STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Q4 2023 Earnings Conference Call March 27, 2024 4:30 PM ET Confere ...

OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such short ...

Exhibit 99.1 STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings Company to host conference call and webcast today, March 27, 2024, at 4:30 PM ET HORSHAM, Pa., Mar. 27, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) ("STRATA" or "the Company"), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the fourth quarter and full-year ended ...

Company Participants Conference Call Participants Operator It is now my pleasure to introduce your host, Rich Cockrell, of Investor Relations. Thank you, Rich. You may begin. Good morning, everyone, and thank you for joining us today. Earlier today, STRATA Skin Sciences released its financial results for the third quarter ended September 30, 2023. A copy of that release is available on the company's website. With us on the call today are Dolev Rafaeli, Vice Chairman, President and Chief Executive Officer; a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ___________ Commission File Number 0-51481 STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other j ...

Destiny Hance Hi. Thank you. This is actually Destiny on for Jeff. I guess can we start kind of following Chris' comments around those international sales. Do you have any additional color to what quarter that will be in? Is it more of a Q4 type of revenue recognition? Or do you think it will be split more evenly between Q3 and Q4? Bob Moccia Yes, this is Bob. Thanks for your question. Yes, we think it's going to probably be more into the Q4 quarter. We'll start to see some rebound in Q3, but we're hearing ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ___________ Commission File Number 0-51481 STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 13-3986004 (State or o ...

Jeffrey Cohen And the coding is per treatment, not per patient? Bob Moccia Per treatment, exactly. Jeffrey Cohen Can you talkÂ… Bob Moccia If you remember, it's four to six treatments per patient. Jeffrey Cohen Can you talk a little bit about Spectra, was there any upfront there? And will the agreement -- it's for both platforms, but will it be both sales of devices as well as for use or will run differently? Bob Moccia So really excited about partnering up with Spectra. They are representing a number of US ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ___________ Commission File Number 0-51481 STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 13-3986004 (State or ...

Thanks. Yes. Thank you for joining us today. We've made great progress on multiple fronts in 2022, and we are excited to continue executing throughout this year. Our goal is to help those who suffer from dermatologic condition. And with the advancements we have made over the past year, we are better equipped to serve them. Thank you again. We look forward to a successful 2023 and catching up in the first quarter. Operator Thank you. That does conclude today's teleconference and webcast. You may disconnect y ...